ea0099rc5.4 | Rapid Communications 5: Pituitary and Neuroendocrinology | Part I | ECE2024
Allas Soraya
, Ravel Guillaume
, Farrell Colm
, Fillon Sophie
, Ould Rouis Taha
, Culler Michael
, Ovize Michel
, Sumeray Mark
, van der Lelij Aart Jan
Background: Acromegaly is a rare disease typically caused by a benign growth hormone (GH)-secreting pituitary adenoma that stimulates over-production of insulin-like growth factor-1 (IGF1) from the liver. Treatment with somatostatin analog (SSA) monotherapy does not provide optimal control of circulating IGF-1 levels in the majority of patients. AZP-3813, a 16-amino acid, bicyclic GH receptor antagonist (GHRA) binds to the GH receptor and prevents endogenous GH from stimulatin...